Melatonin may improve sleep, quality of life in patients with breast cancer
the ONA take:
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
Because fatigue and sleep problems are common among patients with cancer, researchers at the Sunnybrook Odette Cancer Centre in Toronto, Ontario, sought to investigate the effectiveness of melatonin at improving sleep.
For the phase 2 study, researchers enrolled 32 patients with metastatic breast cancer who were receiving hormonal or trastuzumab therapy. All participants took melatonin 5 mg at bedtime for 2 months.
Results showed that bedtime melatonin was associated with a significant improvement in subjective sleep, fatigue severity, sleep fragmentation and quantity, and quality of life.
The findings suggest that further research assessing the efficacy of melatonin for improving sleep and quality of life in patients with cancer is warranted.
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|